Participants described earlier phenotyping, closer tracking of steroid exposure, and recognizing gradual gains on biologic therapy.
|Videos|August 6, 2018
MDS/MPN Overlap Syndromes and Myelofibrosis
Author(s)Aplastic Anemia, MDS International Foundation
Dr. Eric Padrone, a hematologist from H. Lee Moffit Cancer Center, discusses current thinking on MDS/MPN overlap disorders and myelofibrosis.
Advertisement
Dr. Eric Padrone, a hematologist from H. Lee Moffit Cancer Center, discusses current thinking on MDS/MPN overlap disorders and myelofibrosis. Topics include an overview of MDS/MPN overlap disorders and myelofibrosis, current treatment options, and what the future of treatment holds for patients.
Advertisement
Related to this article
Interim IMAgINATION data show the once-monthly factor B antisense therapy sefaxersen reduced proteinuria by 43.1% vs placebo at week 37 in IgA nephropathy.
Interim RAINIER data show povetacicept reduced proteinuria by 52.0% and resolved hematuria in 85% of patients at week 36, ahead of a November PDUFA date.
Interim I CAN data show ravulizumab reduced proteinuria by 43.4% vs placebo at week 34, supporting its FDA accelerated approval in IgA nephropathy.
Lorundrostat cut systolic BP by 9.6 mm Hg and UACR by 52.2% vs placebo in participants with CKD and uncontrolled hypertension in Launch-HTN.
The ENRICH-AF trial ultimately did not demonstrate edoxaban’s efficacy, highlighting the need for further stroke prevention strategies for this patient population.
Final TELIGAN data show telitacicept cut confirmed 30% eGFR decline by 89% and reduced proteinuria by 60.7% vs placebo over 2 years in IgA nephropathy.
Participants described how payer requirements and documentation of steroid exposure shape biologic access.
Advertisement
Advertisement
Trending on HCPLive
1
Retatrutide Lowers Albuminuria, Glomerular Pressure in Obesity and CKD
2
Sleeve Gastrectomy Improves Heart, Kidney MRI Markers in Youth-Onset T2D
3
TELIGAN: Telitacicept Preserves eGFR Through 2 Years in IgA Nephropathy
4
AD109 Yields Numerically Greater OSA Improvements in Postmenopausal Women
5